FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4308378242> ?p ?o ?g. }

• W4308378242 abstract "<h3>Background</h3> Chimeric antigen receptor (CAR) T therapy has shown remarkable success in treating liquid tumours but current approved therapies rely on autologous T cells which are expensive, difficult to manufacture and not readily available for patients whose disease progress rapidly. The production of safe and effective allogeneic CAR-T cells is needed to increase accessibility of CAR-T therapy and broaden its application. The main approach to generate allogeneic CAR-T therapy is by disrupting T cell receptor (TCR) expression to minimize Graft-versus-Host Disease (GVHD) mediated through the TCR of donor cells against the recipient’s major histocompatibility complex (MHC). However, the TCR disruption approach has shown limited persistence <i>in vivo</i> [1] and in clinical trials [2] unlike the long term durability of autologous CAR-T cells. Here, we propose a novel platform for allogeneic CAR-T therapy that retains the TCR but inhibits TCR signalling by knocking out the Lymphocyte-specific protein tyrosine kinase (LCK) – a well-established kinase for proximal TCR activation. This builds on the discovery that our second generation CD28-CAR can be activated independently of LCK unlike the endogenous TCR. <h3>Methods</h3> We utilise the CRISPR-Cas9 system to knockout LCK and TCR in both mouse and human primary T cells. We show how this difference in CAR and TCR signalling can be exploited to generate LCK knockout CAR-T cells that showed similar or enhanced <i>in vitro</i> and <i>in vivo</i> efficacy against tumour cells compared to conventional CAR-T cells of both human and mouse T cell origin. <h3>Results</h3> LCK knockout T cells have reduced proliferation and intracellular cytokine staining against allogeneic PBMCs compared to T cells, suggesting comparable suppression of TCR-mediated alloreactivity to TCR knockout T cells. In the immunodeficient mouse model where human T cells cause xenogeneic GVHD, LCK knockout T cells showed reduced xenogeneic GVHD comparable to TCR knockout T cells. Murine LCK knockout T cells showed the same suppression of TCR signalling as TCR knockout T cells in vitro. In murine major mismatched allogeneic models, murine LCK knockout T cells showed a reduction in GVHD symptoms compared to wild-type T cells. Compared to TCR knockout T cells, the LCK knockout T cells showed superior persistence and higher engraftment in allogeneic recipient mice. <h3>Conclusions</h3> Our study suggests LCK knockout CAR-T cells inhibits TCR-mediated alloreactivity and retains the TCR for improved persistence while maintaining CAR activation potential which results in a superior allogeneic CAR-T therapy compared to TCR knockout CAR-T cells. <h3>References</h3> Stenger, D, Stief, T A, Kaeuferle, T, Willier, S, Rataj, F, Schober, K, Vick, B, Lotfi, R, Wagner, B, Grünewald, T G P, Kobold, S, Busch, D H, Jeremias, I, Blaeschke, F, & Feuchtinger, T. Endogenous TCR promotes in vivo persistence of CD19-CAR-T cells compared to a CRISPR/Cas9-mediated TCR knockout CAR. <i>Blood</i>. 2020;<b>136</b>(12):1407-1418. Wang, Z, Li, N, Feng, K, Chen, M, Zhang, Y, Liu, Y, Yang, Q, Nie, J, Tang, N, Zhang, X, Cheng, C, Shen, L, He, J, Ye, X, Cao, W, Wang, H, & Han, W. Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors. <i>Cell Mol Immunol</i>. 2021;<b>18</b>(9):2188-2198. <h3>Ethics Approval</h3> Animal Protocols were approved by NUS IACUC (R20-1303). Use of human primary T cells was approved by Institutional Review Board (IRB) (H-19-026)." @default.
• W4308378242 created "2022-11-11" @default.
• W4308378242 creator A5002531713 @default.
• W4308378242 creator A5028923910 @default.
• W4308378242 creator A5040894634 @default.
• W4308378242 creator A5045144457 @default.
• W4308378242 creator A5048025879 @default.
• W4308378242 creator A5055497014 @default.
• W4308378242 creator A5059217967 @default.
• W4308378242 creator A5060069503 @default.
• W4308378242 creator A5067316273 @default.
• W4308378242 date "2022-11-01" @default.
• W4308378242 modified "2023-09-26" @default.
• W4308378242 title "274 LCK knockout CAR-T cells as a novel allogeneic platform" @default.
• W4308378242 doi "https://doi.org/10.1136/jitc-2022-sitc2022.0274" @default.
• W4308378242 hasPublicationYear "2022" @default.
• W4308378242 type Work @default.
• W4308378242 citedByCount "0" @default.
• W4308378242 crossrefType "proceedings-article" @default.
• W4308378242 hasAuthorship W4308378242A5002531713 @default.
• W4308378242 hasAuthorship W4308378242A5028923910 @default.
• W4308378242 hasAuthorship W4308378242A5040894634 @default.
• W4308378242 hasAuthorship W4308378242A5045144457 @default.
• W4308378242 hasAuthorship W4308378242A5048025879 @default.
• W4308378242 hasAuthorship W4308378242A5055497014 @default.
• W4308378242 hasAuthorship W4308378242A5059217967 @default.
• W4308378242 hasAuthorship W4308378242A5060069503 @default.
• W4308378242 hasAuthorship W4308378242A5067316273 @default.
• W4308378242 hasBestOaLocation W43083782421 @default.
• W4308378242 hasConcept C147483822 @default.
• W4308378242 hasConcept C148125776 @default.
• W4308378242 hasConcept C170493617 @default.
• W4308378242 hasConcept C182704531 @default.
• W4308378242 hasConcept C19317047 @default.
• W4308378242 hasConcept C203014093 @default.
• W4308378242 hasConcept C207936829 @default.
• W4308378242 hasConcept C2776090121 @default.
• W4308378242 hasConcept C2777701055 @default.
• W4308378242 hasConcept C3875195 @default.
• W4308378242 hasConcept C502942594 @default.
• W4308378242 hasConcept C55493867 @default.
• W4308378242 hasConcept C86803240 @default.
• W4308378242 hasConcept C8891405 @default.
• W4308378242 hasConcept C95444343 @default.
• W4308378242 hasConceptScore W4308378242C147483822 @default.
• W4308378242 hasConceptScore W4308378242C148125776 @default.
• W4308378242 hasConceptScore W4308378242C170493617 @default.
• W4308378242 hasConceptScore W4308378242C182704531 @default.
• W4308378242 hasConceptScore W4308378242C19317047 @default.
• W4308378242 hasConceptScore W4308378242C203014093 @default.
• W4308378242 hasConceptScore W4308378242C207936829 @default.
• W4308378242 hasConceptScore W4308378242C2776090121 @default.
• W4308378242 hasConceptScore W4308378242C2777701055 @default.
• W4308378242 hasConceptScore W4308378242C3875195 @default.
• W4308378242 hasConceptScore W4308378242C502942594 @default.
• W4308378242 hasConceptScore W4308378242C55493867 @default.
• W4308378242 hasConceptScore W4308378242C86803240 @default.
• W4308378242 hasConceptScore W4308378242C8891405 @default.
• W4308378242 hasConceptScore W4308378242C95444343 @default.
• W4308378242 hasLocation W43083782421 @default.
• W4308378242 hasOpenAccess W4308378242 @default.
• W4308378242 hasPrimaryLocation W43083782421 @default.
• W4308378242 hasRelatedWork W2017019887 @default.
• W4308378242 hasRelatedWork W2037024992 @default.
• W4308378242 hasRelatedWork W2155361572 @default.
• W4308378242 hasRelatedWork W2810420374 @default.
• W4308378242 hasRelatedWork W2914085107 @default.
• W4308378242 hasRelatedWork W2995987578 @default.
• W4308378242 hasRelatedWork W3129904134 @default.
• W4308378242 hasRelatedWork W4283161042 @default.
• W4308378242 hasRelatedWork W4308378242 @default.
• W4308378242 hasRelatedWork W2795042237 @default.
• W4308378242 isParatext "false" @default.
• W4308378242 isRetracted "false" @default.
• W4308378242 workType "article" @default.